Physician profile
Stephen Cross
NPI 1063737351
$11,062.23
in general payments reported to CMS, 2019-2025
27 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $81.32 · 2021: $890 · 2022: $4,087 · 2023: $3,583 · 2024: $865 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,071 · Consulting Fee: $2,475 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,071.25 |
| Consulting Fee | $2,475.00 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $3,237.94 | 2021-2025 | Tecnis Iol, Tecnis Iol |
| Glaukos Corporation | $3,122.72 | 2019-2024 | Kxl System (Not Refurbished), Ce-Marked Kxla System |
| Sun Pharmaceutical Industries INC. | $1,009.41 | 2021-2025 | Cequa, Xelpros |
| Alcon Vision LLC | $744.89 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Sight Sciences, INC. | $429.50 | 2022-2024 | Omni Surgical System |
| Abbvie INC. | $354.94 | 2022-2025 | Durysta, Lumigan, Vuity |
| Bausch & Lomb Americas INC. | $328.45 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $255.67 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $222.63 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $213.95 | 2022-2025 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Allergan, INC. | $169.90 | 2021 | |
| Ivantis, INC | $146.51 | 2021 | |
| Dompe US, INC. | $143.72 | 2019-2025 | Oxervate |
| Rxsight INC | $141.35 | 2024-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Omeros Corporation | $125.00 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $106.62 | 2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Kala Pharmaceuticals, INC. | $63.24 | 2021 | |
| Amgen INC. | $48.78 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $32.55 | 2025 | Xdemvy |
| Hoffmann-La Roche Limited | $25.94 | 2019 | |
| Mallinckrodt Hospital Products INC. | $24.74 | 2022 | |
| Oyster Point Pharma, INC. | $24.64 | 2022 | |
| Ocular Therapeutix, INC. | $20.61 | 2024 | Dextenza |
| Biotissue Holdings INC. | $20.42 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $19.65 | 2020 | |
| Horizon Therapeutics Plc | $16.11 | 2022 | |
| Eyevance Pharmaceuticals LLC | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.